Sofia Mayans, Dan Holmberg, Inficure Bio
InfiCure Bio, Sofia Mayans och Dan Holmberg

Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.

In mid-November Inficure Bio was one of six companies looking for capital investment at the Connect North Women event – an event where female entrepreneurs got to meet a panel of investors, business advisors and other entrepreneurs and pitch for finance to develop their companies.

“We presented our business idea and took part in a Q&A session with the panel, who showed a keen interest in our work and asked lots of relevant questions”, says Sofia Mayans, CEO of Inficure Bio.

“This new event next year is another great opportunity for us. We’ll get to connect with more established investors and tell them all about our exciting plans”.

Inficure Bio is one of three companies from northern Sweden that will now go on to participate in the event ‘Mötesplats Stockholm – The Great Northern Capital Connect’. During the event selected companies will get the opportunity to present themselves to relevant investors, as well as experts from the Mälardalen region. The meeting, in keeping with so many other events being hosted during the ongoing pandemic, will be held digitally.

“This event gives us a fantastic opportunity to get in touch with investors from all over Sweden. These digital investor meetings actually work really well, but of course, we also miss traveling and meeting our customers in other countries,” says Sofia Mayans.

InfiCure Bio has customers in several overseas markets, including the US, Switzerland and Australia. The company has also signed a number of major international agreements, including with publicly listed pharmaceutical manufacturers.

“This is yet more recognition for Inficure Bio and illustrates the company’s potential. I would also like to take this opportunity to congratulate Sofia Mayans on the excellent presentation she made,” says Lena Söderström, Chairwoman of the Board of Inficure Bio.

Inficure Bio has developed a model that makes it easier for pharmaceutical companies to test more quickly and with greater accuracy how well new fibrosis drugs perform. Fibrosis, or scar tissue, is the body’s natural way of repairing damaged and inflamed tissue. If, however, this process continues unchecked, large amounts of fibrosis can accumulate in the tissue, which can compromise organ function. Fibrosis can occur as a consequence of, for example, a fatty liver or other low-intensity inflammatory conditions linked to obesity and type 2 diabetes. Fibrosis contributes to around 40 percent of all deaths in the western world.

For further information please contact:

Sofia Mayans, PhD. CEO, Inficure Bio
+46 70-366 46 66

About Inficure Bio

Inficure Bio is a life science company focused on preclinical development of drugs for treatment of chronic inflammatory and fibrotic conditions. The company has a panel of preclinical models, including a unique model, for studies of chronic inflammation and fibrosis.
Inficure Bio is based on extensive expertise in immunology, inflammation and fibrosis and offers a competent and flexible service in this area.
By conducting preclinical tests, Inficure Bio contributes to the development of new drugs for chronic inflammation and fibrosis, which increases the quality of life of the individuals affected by these diseases. Inficure Bio operates in a global market with customers in e.g. Australia, US and Europe.